Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffry P Simko

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
JCO Precision Oncology|July 12, 2021
Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion SequencingEmmalyn Chen, Clinton L Cario, Lancelote Leong, et al.
European Urology|June 2, 2018
The Diverse Genomic Landscape of Clinically Low-risk Prostate CancerMatthew R Cooperberg, Nicholas Erho, June M Chan, et al.
Scientific Reports|March 4, 2021
Cell-free DNA concentration and fragment size as a biomarker for prostate cancerEmmalyn Chen, Clinton L Cario, Lancelote Leong, et al.
Prostate Cancer and Prostatic Diseases|August 29, 2019
Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillanceAnnika Herlemann, Huei-Chung Huang, Ridwan Alam, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 17, 2018
Polyoma virus-associated carcinomas of the urologic tract: a clinicopathologic and molecular studyDeepika Sirohi, Charlie Vaske, Zack Sanborn, et al.
The Prostate|July 21, 2025
Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following ProstatectomyEmily Chan, Stephanie L Pugh, Jeffry P Simko, et al.
European Urology|May 20, 2014
A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersamplingEric A Klein, Matthew R Cooperberg, Cristina Magi-Galluzzi, et al.
European Urology Oncology|November 14, 2024
Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 TrialsKrishnan R Patel, Paul L Nguyen, James A Proudfoot, et al.
Advances in Radiation Oncology|April 20, 2026
The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202Krishnan R Patel, Stephanie L Pugh, Jeffry P Simko, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2018
Phase I Study of CTT1057, an <sup>18</sup>F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate CancerSpencer C Behr, Rahul Aggarwal, Henry F VanBrocklin, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
JCO Precision Oncology|July 12, 2021
Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion SequencingEmmalyn Chen, Clinton L Cario, Lancelote Leong, et al.
European Urology|June 2, 2018
The Diverse Genomic Landscape of Clinically Low-risk Prostate CancerMatthew R Cooperberg, Nicholas Erho, June M Chan, et al.
Scientific Reports|March 4, 2021
Cell-free DNA concentration and fragment size as a biomarker for prostate cancerEmmalyn Chen, Clinton L Cario, Lancelote Leong, et al.
Prostate Cancer and Prostatic Diseases|August 29, 2019
Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillanceAnnika Herlemann, Huei-Chung Huang, Ridwan Alam, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 17, 2018
Polyoma virus-associated carcinomas of the urologic tract: a clinicopathologic and molecular studyDeepika Sirohi, Charlie Vaske, Zack Sanborn, et al.
The Prostate|July 21, 2025
Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following ProstatectomyEmily Chan, Stephanie L Pugh, Jeffry P Simko, et al.
European Urology|May 20, 2014
A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersamplingEric A Klein, Matthew R Cooperberg, Cristina Magi-Galluzzi, et al.
European Urology Oncology|November 14, 2024
Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 TrialsKrishnan R Patel, Paul L Nguyen, James A Proudfoot, et al.
Advances in Radiation Oncology|April 20, 2026
The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202Krishnan R Patel, Stephanie L Pugh, Jeffry P Simko, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2018
Phase I Study of CTT1057, an <sup>18</sup>F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate CancerSpencer C Behr, Rahul Aggarwal, Henry F VanBrocklin, et al.
Pageof 10